ADAPT - A Patient Registry of the Real-world Use of Orenitram®

FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT00760916 ·Status: WITHDRAWN ·Phase: PHASE3

A Pharmacokinetic Substudy of the TDE-PH-304 Protocol

NCT01934582 ·Status: COMPLETED ·Phase: PHASE3

Study Of Right Ventricular Performance In PAH Patients Treated With Rapid Dose Treprostinil (Remodulin)

NCT02074449 ·Status: COMPLETED

Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients

NCT06317805 ·Status: RECRUITING ·Phase: PHASE4

Tyvaso Dosing and Titration Evaluation: TyTRATE Registry

NCT01799473 ·Status: COMPLETED

Study of Ambrisentan in Participants With Pulmonary Hypertension

NCT00777920 ·Status: COMPLETED ·Phase: PHASE3

An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension

NCT00454558 ·Status: COMPLETED ·Phase: PHASE2

Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension

NCT02893995 ·Status: WITHDRAWN ·Phase: PHASE4

Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH

NCT03016468 ·Status: WITHDRAWN ·Phase: PHASE2

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program

NCT01389206 ·Status: COMPLETED

A Real-World Registry Investigating TReprostInil sodiUM in Pulmonary Hypertension (Re-TRIUMPH)

NCT05553015 ·Status: RECRUITING

Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)

NCT03794583 ·Status: TERMINATED ·Phase: PHASE3

Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years

NCT02276872 ·Status: COMPLETED ·Phase: PHASE2

A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)

NCT04712669 ·Status: COMPLETED ·Phase: PHASE2

A Registry for Patients Taking Uptravi

NCT03278002 ·Status: COMPLETED

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

NCT05203510 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction

NCT03037580 ·Status: TERMINATED ·Phase: PHASE3

Observation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients With Pulmonary Arterial Hypertension

NCT04309838 ·Status: UNKNOWN

Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH

NCT04062565 ·Status: RECRUITING ·Phase: PHASE3

Phase 2 Study of Ambrisentan for Liver Function Test Rescue in Pulmonary Arterial Hypertension

NCT00423592 ·Status: COMPLETED ·Phase: PHASE2

A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).

NCT01305252 ·Status: COMPLETED ·Phase: PHASE4

LenusPro Pump in PAH Treated With Treprostinil

NCT02889315 ·Status: UNKNOWN

Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529

NCT01342952 ·Status: COMPLETED ·Phase: PHASE2

An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension

NCT01027949 ·Status: COMPLETED ·Phase: PHASE3

Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH

NCT03888365 ·Status: COMPLETED